Dipeptidylpeptidase-4 Inhibitors aka DPPIV-inhibitors

Examples
Indications
Contraindications
Contraindication Caution
Mechanism
Inhibition of DPP-4 activity causes an increase in incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) by delaying their breakdown. This increases glucose dependent insulin secretion and reduces glucagon secretion.
Administration
Given orally.
Adverse Reactions
Can cause hypoglycaemia.
Interactions
Combination therapy with other anti-diabetic drugs may increase the risk of hypoglycaemia.
Education
Patient education should include explanations about hypoglycaemia and how to recognise / manage it. Patients should also be informed of the risks of pancreatitis and the symptoms of this.
Pharmacokinetics
Nil of note.